Clinical trials: Sexually Transmitted Infections
Gonorrhea of Pharynx, Gonorrhea
Aztreonam for Pharyngeal Gonorrhea
The Centers for Disease Control and Prevention has identified antimicrobial-resistant (AMR) Neisseria gonorrhoeae (NG) as one of the nation's top three urgent AMR threats.
- Trial name
- NCT03867734
- Testing
- Aztreonam
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- University of Washington
Cervical Cancer, Genital Warts
Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)
The primary purpose of the study is to determine if GARDASIL (V501) with four components is able to prevent cervical cancer, cervical dysplasia, including Cervical Intraepithelial Neoplasia (CIN)(Any Grade) and Adenocarcinoma In…
- Trial name
- NCT00092521
- Testing
- V501, Human Papillomavirus (HPV) 16 Monovalent
- Volunteers
- 5,759 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections, Smoking
Improving the Reach & Effectiveness of Smoking Cessation Services Targeted to Veterans Living With HIV
This project will compare the effectiveness of an HIV-specific comprehensive wellness intervention designed to have broad appeal to smokers living with HIV to the effectiveness of standard care services that include referral to…
- Conditions
- HIV Infections, Smoking, Smoking Cessation
- Trial name
- WISH (NCT04505371)
- Testing
- Wellness Intervention for Smokers with HIV
- Where
- United States
- Volunteers
- 235 people, healthy volunteers welcome
- Sponsor
- Seattle Institute for Biomedical and Clinical Research
HIV/AIDS, PrEP
Pre-Exposure Prophylaxis in the Emergency Department
Despite an increasing armamentarium of behavioral and biomedical HIV prevention methods, since 2010 rates of new infection have remained around 40,000 annually.
- Trial name
- PrEPPED (NCT04429971)
- Testing
- PrEP screening program, PrEP starter pack
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
HIV/AIDS
ENLIGHTEN: Establishing Novel Antiretroviral (ARV) Imaging for Hair to Elucidate Non-Adherence
Purpose: Perform a 3-phase (single dose, multi dose, dose proportionality) study in healthy volunteers using daily tenofovir+emtricitabine, dolutegravir, and maraviroc dosing to quantify intra- and inter-subject variability and…
- Trial name
- ENLIGHTEN (NCT03218592)
- Testing
- Maraviroc Pill, Dolutegravir Pill, Truvada Pill
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
HIV Infections
Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection in Women
This study will evaluate the safety and efficacy of the human monoclonal antibody (mAb) VRC-HIVMAB060-00-AB (VRC01) in preventing HIV-1 infection in high-risk, HIV-uninfected women.
- Trial name
- NCT02568215
- Testing
- VRC01
- Where
- 21 sites in Botswana, Kenya and 5 more
- Volunteers
- 1,924 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Infection, Human Immunodeficiency Virus, HIV Infections
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)
This study will compare safety, efficacy, and tolerability of a two drug regimen of dolutegravir (DTG) plus (+) lamivudine (3TC) administered once daily with DTG plus two nucleoside reverse transcriptase inhibitors (tenofovir…
- Trial name
- NCT02831764
- Testing
- Dolutegravir (DTG), Lamivudine (3TC), Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)
- Where
- 105 sites in United States, Argentina and 16 more
- Volunteers
- 722 people
- Sponsor
- ViiV Healthcare
HIV Infections
Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults
This study will evaluate the safety and immune response to the DNA-HIV-PT123 vaccine used in combination with one of two protein vaccines (Bivalent Subtype C gp120/MF59 or Bivalent Subtype C gp120/AS01B) in healthy…
- Trial name
- NCT02915016
- Testing
- DNA-HIV-PT123 vaccine, Bivalent Subtype C gp120/MF59 vaccine, Bivalent Subtype C gp120/AS01B vaccine
- Where
- 17 sites in United States, South Africa
- Volunteers
- 334 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, HIV-1
TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants
The purpose of this study is to provide etravirine (ETR) through this trial until participants can be switched to locally available ETR-based treatment regimens (that is, commercially available and reimbursed, or accessible…
- Trial name
- NCT00980538
- Testing
- Etravirine
- Where
- 29 sites in United States, Argentina and 9 more
- Volunteers
- 180 people
- Sponsor
- Janssen Sciences Ireland UC
Genital Herpes
Effect of HSV-2 Suppressive Therapy on Sexual Behavior
The purpose of this study is to determine what effect suppressive therapy has on sexual behavior and quality of life among persons with genital herpes (HSV) who have multiple sex partners.
- Trial name
- NCT00495716
- Testing
- acyclovir
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- University of Washington
HIV, STI
Parrying the Pitfalls of PrEP: Project PEACH
The study is a prospective cohort of young MSM who are followed for 2 years either in-person at the PRISM Health Research Clinic and/or virtually with telehealth study visits.
- Trial name
- NCT05072093
- Testing
- PrEP discontinuation intervention, Offering of on-demand oral PrEP, Offering of STI PEP
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Emory University
Inflammation, Coagulation
Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease
The purpose of this study is to evaluate the effects of pharmacologic FXa inhibition (via edoxaban 30 mg daily) on inflammation, as reflected in plasma Interleukin-6 levels.
- Conditions
- Inflammation, Coagulation, HIV Infection
- Trial name
- TACTICAL-HIV (NCT02339415)
- Testing
- Edoxaban 30mg daily
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- Hennepin Healthcare Research Institute
HIV Seropositivity
Early Community Client-LED ART Delivery in Nakivale Refugee Settlement
To pilot early community client-led ART (anti-retroviral therapy) delivery (CCLAD) in Nakivale Refugee Settlement in Uganda and assess the feasibility and acceptability of this intervention in this setting.
- Trial name
- Early CCLAD (NCT04736316)
- Testing
- Early CCLAD
- Where
- Uganda
- Volunteers
- 92 people
- Sponsor
- University of Washington
Infections, Papillomavirus
A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Papillomavirus Vaccine (GSK-580299) in Chinese Females
A phase I, open label, single-centre study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' HPV -16/18 L1 VLP AS04 vaccine (GSK 580299, Cervarix TM), administered intramuscularly according to a 0, 1…
- Trial name
- NCT00549900
- Testing
- GSK580299 (Cervarix™ , HPV -16/18 L1 VLP AS04 vaccine)
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Immunodeficiency Virus (HIV), HIV Associated Neurocognitive Disorders (HAND)
A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac)
HIV related cognitive impairment still occurs despite highly active antiretroviral therapy (HAART). HIV disease affects the brain in 20-40% of patients with advancing HIV disease; leading to varying degrees of cognitive…
- Trial name
- HANDmac (NCT01449006)
- Testing
- Maraviroc
- Where
- 2 sites in Australia
- Volunteers
- 19 people
- Sponsor
- Bruce Brew
Chlamydia Infection, Gonococcal Infection
Use of Abbott RealTime CT/NG to Detect Chlamydia Trachomatis [CT] & Neisseria Gonorrhoeae [NG] in Men Who Have Sex With Men [MSM]
Julius Schachter, PhD, (Department of Laboratory Medicine, University of California, San Francisco) and Susan S. Philip, MD MPH (Department of Medicine, University of California, San Francisco) are conducting a study to evaluate…
- Conditions
- Chlamydia Infection, Gonococcal Infection, Sexually Transmitted Diseases
- Trial name
- NCT01291264
- Where
- 2 sites in United States
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Pharyngeal Gonococcal Infection
Gent for Pharyngeal Gonorrhea (GC)
The Centers for Disease Control and Prevention has identified antimicrobial-resistant (AMR) Neisseria gonorrhoeae (NG) as one of the nation's top three urgent AMR threats.
- Trial name
- NCT03632109
- Testing
- gentamicin 360mg IM
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Washington
Hiv, HIV/AIDS
AllyQuest Adherence App Intervention for HIV-positive Men Who Have Sex With Men and Transgender Women: Pilot Trial
AllyQuest (AQ) is a theory-informed smart phone application that supports HIV medication adherence for young men who have sex with men and young transgender women who have sex with men (YMSM/YTW) via behavior change, social…
- Conditions
- Hiv, HIV/AIDS, Medication Adherence, Sexual Behavior
- Trial name
- AQ2 (NCT03916484)
- Testing
- AllyQuest HIV Medication Adherence app-delivered intervention, AllyQuest HIV Medication Adherence app-delivered intervention + NSC
- Where
- 6 sites in United States
- Volunteers
- 71 people
- Sponsor
- University of North Carolina, Chapel Hill
Gonorrhoea
A Study to Evaluate the Safety, Tolerability and Plasma PK of a Single Oral Dose of Zoliflodacin in Healthy Male and Female Volunteers
The trial is to evaluate the pharmacokinetics and safety profiles of the single-dose of zoliflodacin in eight healthy male or female subjects ages 18 to 45 years inclusive.
- Trial name
- NCT03404167
- Testing
- AZD0914
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection
A Safety and Immune Response Study of 2 Experimental HIV Vaccines
The HIV Vaccine Trials Network (HVTN) is doing a study to test a new HIV vaccine combination. HIV is the virus that causes AIDS. 252 people are taking part in this study at multiple sites.
- Trial name
- NCT02404311
- Testing
- ALVAC-HIV, Bivalent Subtype C gp120/MF59®
- Where
- 5 sites in South Africa
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.